Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA in Combination With a Hypomethylating Agent for Relapsed/Refractory MDS, CMML, and AML
NCT03146871Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sephb4-hsa in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by University of Southern California. Started Apr 2017; status: terminated.
02
Drugs
sephb4-hsa
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03146871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146871.